ATEC Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Given the user's beginner investment level, long-term strategy, and available capital, Alphatec Holdings Inc (ATEC) is not a strong buy at this time. Despite positive revenue growth and analyst optimism, the company's negative net income, declining EPS, and bearish technical indicators suggest caution. Hold for now and monitor for improved financial performance or stronger technical signals.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 59.804, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near a key pivot level of 13.576, with resistance at 14.216 and support at 12.936. Overall, the technical indicators are mixed, leaning bearish.
Revenue growth of 20.44% YoY in Q4
Analysts maintain positive ratings with price targets ranging from $20 to $27, indicating potential upside.
Hedge funds are significantly increasing their positions, with a 316.57% rise in buying activity over the last quarter.
Declining net income (-34.81% YoY) and EPS (-39.13% YoY) in Q4
Bearish moving averages and a post-market price decline of -1.93%.
Stock trend analysis indicates a likelihood of negative short-term performance (-0.95% next day, -0.39% next week, -1.58% next month).
In Q4 2025, Alphatec reported revenue of $213 million, up 20.44% YoY, and a gross margin increase to 68.39%. However, net income dropped to -$21.73 million (-34.81% YoY), and EPS fell to -$0.14 (-39.13% YoY). The company projects 17% revenue growth for 2026.
Analysts are optimistic about ATEC's growth potential, with TD Cowen lowering the price target to $20 but maintaining a Buy rating. Barclays raised the price target to $27, citing strong industry positioning. Freedom Capital initiated coverage with a Buy rating and a $25 price target. Morgan Stanley raised its price target to $23, highlighting favorable MedTech industry conditions.
